Immunic Gross Profit from 2010 to 2024

IMUX Stock

USD 1.11 0.02 1.77%

Immunic Gross Profit yearly trend continues to be fairly stable with very little volatility. Gross Profit is likely to outpace its year average in 2024. Gross Profit is the profit Immunic makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. View All Fundamentals

Gross Profit

First Reported

2010-12-31

Previous Quarter

-111 K

Current Value

-105.5 K

Quarterly Volatility

44.6 K

Credit Downgrade

Yuan Drop

Covid

Check Immunic financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immunic's main balance sheet or income statement drivers, such as Depreciation And Amortization of 105.5 K, Interest Expense of 730.2 K or Other Operating Expenses of 54.8 M, as well as many indicators such as Price To Sales Ratio of 17.3 K, Dividend Yield of 0.0064 or PTB Ratio of 1.46. Immunic financial statements analysis is a perfect complement when working with Immunic Valuation or Volatility modules.

Check out the analysis of Immunic Correlation against competitors.

For more information on how to buy Immunic Stock please use our How to Invest in Immunic guide.

Latest Immunic's Gross Profit Growth Pattern

Below is the plot of the Gross Profit of Immunic over the last few years. Gross profit is a required income statement account that reflects total revenue of Immunic minus its cost of goods sold. It is profit before Immunic operating expenses, interest payments and taxes. Gross profit is also known as gross margin. It is the profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. Immunic's Gross Profit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Immunic's overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 0

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Gross Profit

Timeline

Immunic Gross Profit Regression Statistics

	Arithmetic Mean	(32,120)
	Geometric Mean	18,211
	Coefficient Of Variation	(138.98)
	Mean Deviation	39,015
	Median	(4,908)
	Standard Deviation	44,641
	Sample Variance	2B
	Range	116.8K
	R-Value	(0.92)
	Mean Square Error	347.9M
	R-Squared	0.84
	Slope	(9,137)
	Total Sum of Squares	27.9B

Immunic Gross Profit History

	2024	-105.5 K
	2023	-111 K
	2022	-77 K
	2021	-85 K
	2020	-39 K
	2018	-50 K
	2017	-4908.0

Other Fundumenentals of Immunic

Gross Profit Margin

Immunic Gross Profit component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Short Term Debt	Short Term Investments	Common Stock	Net Tangible Assets	Capital Surpluse	Property Plant Equipment	Net Receivables	Intangible Assets	Net Invested Capital	Net Working Capital	Capital Stock	Current Deferred Revenue
Total Assets		0.96	-0.95	-0.04	0.57	-0.53	0.97	-0.23	-0.48	0.28	0.34	0.15	-0.41	0.72	0.44	0.78	0.74	-0.41	0.28
Total Stockholder Equity	0.96		-0.94	-0.04	0.55	-0.73	0.93	-0.14	-0.6	0.32	0.18	0.13	-0.38	0.59	0.42	0.71	0.66	-0.4	0.15
Net Debt	-0.95	-0.94		0.03	-0.68	0.56	-0.98	0.34	0.49	-0.36	-0.36	-0.24	0.25	-0.61	-0.28	-0.68	-0.7	0.2	-0.17
Retained Earnings	-0.04	-0.04	0.03		0.13	0.19	-0.09	-0.15	0.3	-0.84	0.12	-0.79	0.52	-0.22	-0.47	0.19	0.13	-0.27	-0.64
Accounts Payable	0.57	0.55	-0.68	0.13		-0.33	0.65	-0.33	-0.41	0.24	0.3	0.14	0.07	0.19	-0.01	0.12	0.15	0.07	0.19
Total Liab	-0.53	-0.73	0.56	0.19	-0.33		-0.52	-0.16	0.79	-0.38	0.36	-0.06	0.25	-0.07	-0.27	-0.17	-0.1	0.25	0.07
Total Current Assets	0.97	0.93	-0.98	-0.09	0.65	-0.52		-0.35	-0.45	0.38	0.4	0.28	-0.32	0.71	0.34	0.7	0.73	-0.21	0.3
Short Term Debt	-0.23	-0.14	0.34	-0.15	-0.33	-0.16	-0.35		-0.17	0.06	-0.68	-0.18	-0.55	-0.19	0.57	-0.25	-0.42	-0.47	-0.02
Short Term Investments	-0.48	-0.6	0.49	0.3	-0.41	0.79	-0.45	-0.17		-0.45	0.3	-0.12	0.34	0.06	-0.32	0.0	0.12	0.27	-0.11
Common Stock	0.28	0.32	-0.36	-0.84	0.24	-0.38	0.38	0.06	-0.45		-0.08	0.87	-0.45	0.25	0.45	-0.07	0.01	0.34	0.55
Net Tangible Assets	0.34	0.18	-0.36	0.12	0.3	0.36	0.4	-0.68	0.3	-0.08		0.32	0.07	0.5	0.01	0.45	0.57	0.25	0.32
Capital Surpluse	0.15	0.13	-0.24	-0.79	0.14	-0.06	0.28	-0.18	-0.12	0.87	0.32		-0.34	0.36	0.38	-0.03	0.12	0.59	0.67
Property Plant Equipment	-0.41	-0.38	0.25	0.52	0.07	0.25	-0.32	-0.55	0.34	-0.45	0.07	-0.34		-0.49	-0.93	-0.29	-0.18	0.5	-0.54
Net Receivables	0.72	0.59	-0.61	-0.22	0.19	-0.07	0.71	-0.19	0.06	0.25	0.5	0.36	-0.49		0.53	0.76	0.8	-0.19	0.6
Intangible Assets	0.44	0.42	-0.28	-0.47	-0.01	-0.27	0.34	0.57	-0.32	0.45	0.01	0.38	-0.93	0.53		0.35	0.22	-0.44	0.55
Net Invested Capital	0.78	0.71	-0.68	0.19	0.12	-0.17	0.7	-0.25	0.0	-0.07	0.45	-0.03	-0.29	0.76	0.35		0.96	-0.47	0.05
Net Working Capital	0.74	0.66	-0.7	0.13	0.15	-0.1	0.73	-0.42	0.12	0.01	0.57	0.12	-0.18	0.8	0.22	0.96		-0.22	0.08
Capital Stock	-0.41	-0.4	0.2	-0.27	0.07	0.25	-0.21	-0.47	0.27	0.34	0.25	0.59	0.5	-0.19	-0.44	-0.47	-0.22		0.15
Current Deferred Revenue	0.28	0.15	-0.17	-0.64	0.19	0.07	0.3	-0.02	-0.11	0.55	0.32	0.67	-0.54	0.6	0.55	0.05	0.08	0.15

Click cells to compare fundamentals

About Immunic Financial Statements

Immunic investors use historical fundamental indicators, such as Immunic's Gross Profit, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Immunic. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Gross Profit	-111 K	-105.5 K
Gross Profit Margin	(256.77)	(269.61)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for Immunic Stock Analysis

When running Immunic's price analysis, check to measure Immunic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunic is operating at the current time. Most of Immunic's value examination focuses on studying past and present price action to predict the probability of Immunic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunic's price. Additionally, you may evaluate how the addition of Immunic to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC